| Autor: |
Bulloch MN; University of Alabama-Tuscaloosa School of Medicine, Department of Internal Medicine, University Medical Center, Box 870326, Tuscaloosa, AL 35487, USA. mjn0004@auburn.edu, Elayan MM, Renfroe HR |
| Jazyk: |
angličtina |
| Zdroj: |
Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2011 Nov; Vol. 4 (6), pp. 685-92. |
| DOI: |
10.1586/ecp.11.60 |
| Abstrakt: |
Sipuleucel-T is a therapeutic cancer vaccine approved for the treatment of castration- or hormone-refractory prostate cancer. Through a novel process, it activates the body's own antigen-presenting cells to induce an immune response to prostatic acid phosphatase, a protein found on prostate cancer cells. A treatment course consists of three total infusions spread 2 weeks apart. Throughout all phases of clinical trials, sipuleucel-T has been shown to be safe and well tolerated. Sipuleucel-T has demonstrated an ability to increase overall survival by approximately 4 months when compared with placebo. However, sipuleucel-T has not shown any improvement in affecting patients' time to disease progression. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
